Firstly, because the clinical data simultaneously evaluating all available first-line treatments for advanced EGFR mutated NSCLC in one clinical trial is not available, this economic evaluation was based on a recently published NMA. This evidence concerns the gene EGFR and non-small cell lung carcinoma.